Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361822018> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W4361822018 abstract "<div>Abstract<p>The PI3K–AKT pathway is hyperactivated in many human cancers, and several drugs to inhibit this pathway, including the PI3K/mTOR dual inhibitor NVP-BEZ235, are currently being tested in various preclinical and clinical trials. It has been shown that pharmacologic inhibition of the PI3K–AKT pathway results in feedback activation of other oncogenic signaling pathways, which likely will limit the clinical utilization of these inhibitors in cancer treatment. However, the underlying mechanisms of such feedback regulation remain incompletely understood. The PI3K–AKT pathway is a validated therapeutic target in renal cell carcinoma (RCC). Here, we show that FoxO transcription factors serve to promote AKT phosphorylation at Ser473 in response to NVP-BEZ235 treatment in renal cancer cells. Inactivation of FoxO attenuated NVP-BEZ235–induced AKT Ser473 phosphorylation and rendered renal cancer cells more susceptible to NVP-BEZ235–mediated cell growth suppression <i>in vitro</i> and tumor shrinkage <i>in vivo</i>. Mechanistically, we showed that FoxOs upregulated the expression of Rictor, an essential component of MTOR complex 2, in response to NVP-BEZ235 treatment and revealed that Rictor is a key downstream target of FoxOs in NVP-BEZ235–mediated feedback regulation. Finally, we show that FoxOs similarly modulate the feedback response on AKT Ser473 phosphorylation and renal tumor growth by other phosphoinositide 3-kinase (PI3K) or AKT inhibitor treatment. Together, our study reveals a novel mechanism of PI3K–AKT inhibition-mediated feedback regulation and may identify FoxO as a novel biomarker to stratify patients with RCC for PI3K or AKT inhibitor treatment, or a novel therapeutic target to synergize with PI3K–AKT inhibition in RCC treatment. <i>Cancer Res; 74(6); 1682–93. ©2014 AACR</i>.</p></div>" @default.
- W4361822018 created "2023-04-05" @default.
- W4361822018 creator A5023663301 @default.
- W4361822018 creator A5035169366 @default.
- W4361822018 creator A5040388557 @default.
- W4361822018 creator A5047839791 @default.
- W4361822018 creator A5052286157 @default.
- W4361822018 creator A5067510351 @default.
- W4361822018 date "2023-03-30" @default.
- W4361822018 modified "2023-10-16" @default.
- W4361822018 title "Data from FoxO Transcription Factors Promote AKT Ser473 Phosphorylation and Renal Tumor Growth in Response to Pharmacologic Inhibition of the PI3K–AKT Pathway" @default.
- W4361822018 doi "https://doi.org/10.1158/0008-5472.c.6505859" @default.
- W4361822018 hasPublicationYear "2023" @default.
- W4361822018 type Work @default.
- W4361822018 citedByCount "0" @default.
- W4361822018 crossrefType "posted-content" @default.
- W4361822018 hasAuthorship W4361822018A5023663301 @default.
- W4361822018 hasAuthorship W4361822018A5035169366 @default.
- W4361822018 hasAuthorship W4361822018A5040388557 @default.
- W4361822018 hasAuthorship W4361822018A5047839791 @default.
- W4361822018 hasAuthorship W4361822018A5052286157 @default.
- W4361822018 hasAuthorship W4361822018A5067510351 @default.
- W4361822018 hasConcept C104317684 @default.
- W4361822018 hasConcept C107846503 @default.
- W4361822018 hasConcept C11960822 @default.
- W4361822018 hasConcept C127561419 @default.
- W4361822018 hasConcept C140149449 @default.
- W4361822018 hasConcept C168003608 @default.
- W4361822018 hasConcept C185592680 @default.
- W4361822018 hasConcept C502942594 @default.
- W4361822018 hasConcept C55493867 @default.
- W4361822018 hasConcept C62478195 @default.
- W4361822018 hasConcept C75217442 @default.
- W4361822018 hasConcept C86554907 @default.
- W4361822018 hasConcept C86803240 @default.
- W4361822018 hasConcept C95444343 @default.
- W4361822018 hasConcept C98490376 @default.
- W4361822018 hasConceptScore W4361822018C104317684 @default.
- W4361822018 hasConceptScore W4361822018C107846503 @default.
- W4361822018 hasConceptScore W4361822018C11960822 @default.
- W4361822018 hasConceptScore W4361822018C127561419 @default.
- W4361822018 hasConceptScore W4361822018C140149449 @default.
- W4361822018 hasConceptScore W4361822018C168003608 @default.
- W4361822018 hasConceptScore W4361822018C185592680 @default.
- W4361822018 hasConceptScore W4361822018C502942594 @default.
- W4361822018 hasConceptScore W4361822018C55493867 @default.
- W4361822018 hasConceptScore W4361822018C62478195 @default.
- W4361822018 hasConceptScore W4361822018C75217442 @default.
- W4361822018 hasConceptScore W4361822018C86554907 @default.
- W4361822018 hasConceptScore W4361822018C86803240 @default.
- W4361822018 hasConceptScore W4361822018C95444343 @default.
- W4361822018 hasConceptScore W4361822018C98490376 @default.
- W4361822018 hasLocation W43618220181 @default.
- W4361822018 hasOpenAccess W4361822018 @default.
- W4361822018 hasPrimaryLocation W43618220181 @default.
- W4361822018 hasRelatedWork W1966019502 @default.
- W4361822018 hasRelatedWork W1988963518 @default.
- W4361822018 hasRelatedWork W2016514257 @default.
- W4361822018 hasRelatedWork W2167795228 @default.
- W4361822018 hasRelatedWork W2591452418 @default.
- W4361822018 hasRelatedWork W2912656088 @default.
- W4361822018 hasRelatedWork W3213848811 @default.
- W4361822018 hasRelatedWork W4238567307 @default.
- W4361822018 hasRelatedWork W4313356770 @default.
- W4361822018 hasRelatedWork W4361822018 @default.
- W4361822018 isParatext "false" @default.
- W4361822018 isRetracted "false" @default.
- W4361822018 workType "article" @default.